Combination treatments and compositions for wound healing comprising viral VEGF
AssigneeOtago Innovation Limited
InventorsLyn Marie Wise, Stephen Bruce Fleming, Andrew Allan Mercer
Life of this patent
Estimating the term…
Abstract
Viral VEGF and viral anti-inflammatory cytokine compositions, methods of treatment using them, and kits containing them for use in the promotion and/or improvement of wound healing and/or tissue repair, and for anti-scarring, anti-inflammatory, anti-fibrosis and anti-adhesion indications.
Claims31
A method of treating a subject having a wound not healing at an expected rate, which comprises administration of an effective amount of a viral VEGF selected from the group consisting of a parapoxvirus VEGF E and an orf virus VEGF-E, and (ii) an anti-inflammatory cytokine, optionally a viral anti-inflammatory cytokine, optionally a viral anti-inflammatory interleukin, optionally viral IL-10, to a subject in need of treatment therewith, wherein said viral VEGF-E and said viral anti-inflammatory cytokine are administered in combination or administered separately.
A composition comprising a viral VEGF selected from the group consisting of a parapoxvirus VEGF-E and an orf virus VEGF-E and a viral anti-inflammatory cytokine effective to promote wound healing and a pharmaceutically acceptable carrier, wherein the composition optionally is formulated for administration via a route selected from the group consisting of topical administration and injection.
A method of manufacture of a medicament comprising bringing together amounts of a viral VEGF selected from the group consisting of a parapoxvirus VEGF-E and an orf virus VEGF-E and a viral anti-inflammatory cytokine effective to promote wound healing and a pharmaceutically acceptable carrier.
An article of manufacture comprising package material containing therapeutically effective amounts of a viral VEGF selected from the group consisting of a parapoxvirus VEGF-E and an orf virus VEGF-E and a viral anti-inflammatory cytokine together with instructions for use in the treatment of a wound in or on a subject.
An article comprising package material containing therapeutically effective amounts of each of (i) a viral VEGF selected from the group consisting of a parapoxvirus VEGF-E and an orf virus VEGF-E, and (ii) an anti-inflammatory cytokine, optionally a viral anti-inflammatory cytokine, optionally a viral anti-inflammatory interleukin, optionally viral IL-10, together with instructions for use in the treatment of a wound in or on a subject.
A composition comprising a viral VEGF selected from the group consisting of a parapoxvirus VEGF-E and an orf virus VEGF-E and a mammalian anti-inflammatory cytokine effective to promote wound healing and a pharmaceutically acceptable carrier, wherein the composition optionally is formulated for administration via a route selected from the group consisting of topical administration and injection.
An article of manufacture comprising package material containing therapeutically effective amounts of a viral VEGF selected from the group consisting of a parapoxvirus VEGF-E and an orf virus VEGF-E and a mammalian anti-inflammatory cytokine together with instructions for use in the treatment of a wound in or on a subject.
Dependencies are inferred from the claim text.